Feb 9, 2026
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Feb 3, 2026
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Jan 6, 2026
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Jan 5, 2026
Estrella Immunopharma Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Dec 4, 2025
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Nov 3, 2025
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Oct 6, 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
Jun 5, 2025
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Jun 3, 2025
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
May 29, 2025
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
Mar 5, 2025
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating with a Price Target of $14.00 from CB Capital Partners
Feb 21, 2025
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
